<DOC>
	<DOCNO>NCT00244426</DOCNO>
	<brief_summary>Evaluate efficacy safety Indobufen v. Aspirin prevent thromboembolic event patient high risk CV event patient suffer nonrheumatic atrial fibrillation .</brief_summary>
	<brief_title>S.I.F.A . II : Prevention Of Thromboembolic Events In Patients With Nonrheumatic Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Indobufen</mesh_term>
	<criteria>Chronic paroxysmal non rheumatic atrial fibrillation cardioembolic risk factor : hypertension , ischemic cardiopathy , Congestive Heart Failure , diabetes mellitus Clinically relevant organ disease creatinine clearance &lt; 30 ml/min gastric duodenal ulcer severe anaemia poliglobulia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Prevention thromboembolic event patient non valvular atrial fibrillation</keyword>
</DOC>